SCHEMBL1676523

SCHEMBL1676523

O=C(O)c1ccc(Cn2cc(-c3ccc(Cl)cc3Cl)nc2/C=C/c2ccc(-c3cccc(NS(=O)(=O)CC(F)(F)F)c3)cc2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B1 P14061 1/20 0.36
HSD17B2 P37059 1/20 0.36
ENPP2 Q13822 1/20 0.34
SYK P43405 1/20 0.33
PTGER4 P35408 3/20 0.33
PTGDR Q13258 3/20 0.33
ADRB2 P07550 1/20 0.32
ADRB1 P08588 1/20 0.32
ADRB3 P13945 1/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
POLB P06746 1/20 0.32
HPGD P15428 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1676527 1.00 RAB9A (0.37) RAB9AKDM4ENPC1CRHBPCRHR2
SCHEMBL12736660 0.95 RAB9A (0.36) RAB9AKDM4ENPC1CRHBPCRHR2
SCHEMBL1676368 0.94 KDM4E (0.39) RAB9AKDM4ENPC1CRHBPCRHR2
SCHEMBL1676370 0.94 KDM4E (0.39) RAB9AKDM4ENPC1CRHBPCRHR2
SCHEMBL1676577 0.93 DRD2 (0.40) HSD17B1HSD17B2POLBF2
SCHEMBL1676579 0.93 DRD2 (0.40) HSD17B1HSD17B2POLBF2
SCHEMBL1483842 0.92 PPARA (0.38) RAB9AKDM4ENPC1CRHBPCRHR2
SCHEMBL1483845 0.92 PPARA (0.38) RAB9AKDM4ENPC1CRHBPCRHR2
SCHEMBL1676788 0.90 HSD17B1 (0.36) RAB9AKDM4ENPC1CRHBPCRHR2
SCHEMBL1676792 0.90 HSD17B1 (0.36) RAB9AKDM4ENPC1CRHBPCRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use TRANSTECH PHARMA, INC. (US) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092553-A1 Substituted Azole Derivatives, Compositions, and Methods of Use PTPRO, PTPN5, PTPRE RAB9A 3396/4885KDM4E 733/4885NPC1 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.